Progress in Hepatocellular Carcinoma TreatmentK. Okita Springer Science & Business Media, 1999 - 107 pages According to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC. |
Contents
The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea | 1 |
Percutaneous Ethanol Injection Therapy Percutaneous Infarction Therapy and Percutaneous Microwave Coagulation Therapy for Hepatocellular Car... | 10 |
Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma | 17 |
Percutaneous Ablation of Hepatocellular Carcinoma | 23 |
Prognosis Recurrence and Effect on Liver Function | 35 |
Clinical Significance of LiposomeEncapsulated OK432 Injection with Simultaneous Interventional Radiological Treatment of Hepatocellular Carcino... | 40 |
Phase II Trial of Hepatic Arterial Infusion Chemotherapy Using Cisplatin and 5Fluorouracil in Patients with Advanced Hepatocellular Carcinoma | 49 |
Surgical Treatment of Hepatocellular Carcinoma | 56 |
Transjugular Intrahepatic Portosystemic Shunt for Patients with Hepatocellular Carcinoma | 64 |
Prevention of Hepatocarcinogenesis by Fibrosuppression | 76 |
Cancer Vaccination by B71Transfected Hepatocellular Carcinoma Cells | 86 |
A Clinical Experience in Liver Cancer | 97 |
105 | |
Other editions - View all
Common terms and phrases
ablation acyclic retinoid anatomic resection apoptosis ascites Cancer Phila carcinogenesis CDAA diet chemotherapy chronic hepatitis cisplatin clinical clonal deletion cytolytic cytolytic activity Department of Internal detection distant recurrence effect electrode ethanol injection therapy fed a CDAA fibrosis GSTP-positive lesions HCC cell lines HCC development Hep3B cells hepatectomy hepatic arterial infusion hepatic artery hepatic resection hepatic vein hepatocellular carcinoma hepatocellular carcinoma HCC Hepatol Hepatology hepatoma human HCC cells hydroxyproline induced intermediate TCR cells Internal Medicine Japan LC(C lipiodol liposomes liver cancer liver cirrhosis liver neoplasms Livraghi metastasis mice mmHg multivariate analysis necrosis needle OK-Lipo patients with hepatocellular PEIT Percutaneous ethanol injection performed PMCT portal vein prognosis prognostic factors prolyl 4-hydroxylase Radiology rats fed receptor screening serum Shiina shunt significantly small hepatocellular carcinoma STAE survival rate tissue transcatheter arterial embolization transfected treatment of hepatocellular tumor type of hepatectomy Uncontrollable ascites unencapsulated OK-432 varices Yamaguchi